Nektar wants everyone to stay calm as they carry on with NKTR-214, but #ASCO18 spurs a stampede
CHICAGO — Bristol-Myers Squibb $BMY has gone all in on Nektar’s $NKTR approach to amping up their checkpoint strategy, partnering on NKTR-214. But instead of taking a bow at #ASCO18 on positive data, researchers spent the weekend explaining why their latest data readout from a small study shouldn’t be cause for panic.
It’s not what they were looking for, to put it mildly.
Unlike most of the more closely-watched programs here at ASCO, the researchers involved never offered a preview of the data that came out Saturday evening. And that was a serious misstep, particularly as the reporters covering this session struggled to figure out what was being reported — and what it meant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.